Wednesday, 17 April 2024

 

 

LATEST NEWS Punjab Police Solves Murder Case Of VHP Leader Within 72 Hours; Two Assailants Held Bihar Cadre IAS Officers Visited SAS Nagar Administration is ensuring smooth procurement operations in district- Sakshi Sawhney Amarinder Singh Raja Warring Seeks Blessings At Shri Maa Chintpurni Temple Shayar: 5 Reasons To Watch Neeru Bajwa And Satinder Sartaaj Shine Haryana Chief Secretary pays tribute to Baba Saheb Dr. Bhimrao Ambedkar's on 133rd birth anniversary AAP announces remaining four LS candidates in Punjab 6 Best Jonita D'Cruz Web Series To Watch [List Updated 2024] AAP LS candidate Umesh Makwana filed his nomination papers in the presence of Bhagwant Mann Actress Malaika Arora presents NariFirst Jewel of India Crown to Eesha Agrawal as Empress in Historic Beauty Pageant Gurjit Singh Aujla was warmly welcomed at the railway station, Senior Congress leaders, workers and city residents showered flowers Applying For NEET PG 2024: Essential Steps and Important Dates 'Falahar Grahan Program’ organized at Raj Bhavan LPU Sets World Record with Largest Display of Macarons Samaira Sandhu Credits Yoga for Transforming Her life District Records Wheat Arrival of Over 10,000 MT Rubina Dilaik Net Worth 2024: From Television Star to Bollywood Debut - Net Worth & Beyond CGC’s Biotechnology department organises event on bioentrepreneurship RBU, NMSU sign MoU to forge strategic collaboration Hasta La Vista Fresher and Farewell Party at GJIMT, Mohali 50,000 Strong Punjab Cong Cadre Will Dismantle Bjp: Amarinder Singh Raja Warring

 

UK approves world’s 1st gene therapy to treat sickle-cell, Thalassemia

Health, Study, Research, Researchers, World News, World First Gene Therapy, World First Gene Therapy Thalassemia, Thalassemia, Thalassemia Gene Therapy, Sickle Cell Gene Therapy, Gene Therapy Sickle Cell, World First Gene Therapy Sickle Cell
Listen to this article

Web Admin

Web Admin

5 Dariya News

London , 18 Nov 2023

The UK has approved the world's first gene therapy to treat blood disorders sickle-cell disease and thalassemia using the gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020.So far, a bone marrow transplant which must come from a closely matched donor and carries a risk of rejection has been the only permanent treatment option.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorised the new treatment called Casgevy for patients with sickle-cell disease and transfusion-dependent beta-thalassemia aged 12 and over.

Both sickle cell disease and beta-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body.Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin.

To do this, stem cells are taken out of bone marrow, edited in a laboratory and then infused back into the patient after which the results have the potential to be life-long. In people with sickle cell disease, the genetic error can lead to attacks of very severe pain, serious and life-threatening infections, and anaemia (whereby your body has difficulty carrying oxygen). 

Among beta-thalassaemia patients, it can lead to severe anaemia. Patients often need a blood transfusion every 3 to 5 weeks, and injections and medicines throughout their lives.“Both sickle cell disease and beta-thalassemia are painful, life-long conditions that in some cases can be fatal,” said Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, in a statement.

“We have authorised an innovative and first-of-its-kind gene-editing treatment called Casgevy, which in trials has been found to restore healthy haemoglobin production in the majority of participants with sickle-cell disease and transfusion-dependent beta-thalassaemia, relieving the symptoms of disease,” she added.

Casgevy’s approval for sickle-cell disease was based on a clinical trial of 29 patients, of which 28 (97 per cent) were free of severe pain crises for at least 12 months after treatment.Of the 42 patients in the clinical trial for transfusion-dependent beta-thalassemia, 39 (93 per cent) did not need a red blood cell transfusion for at least 12 months after treatment. The remaining three had more than a 70 per cent reduction in the need for red cell transfusions.

Side effects from treatment were similar to those associated with autologous (from a person’s own cells) stem cell transplants, including (but not limited to) nausea, fatigue, fever and increased risk of infection.

No significant safety concerns were identified during the trials, the MHRA said, adding that the safety of the treatment will be analysed further. Casgevy is currently being evaluated by the US Food and Drug Administration (FDA) and is expected to receive the agency’s approval next month.

 

Tags: Health , Study , Research , Researchers , World News , World First Gene Therapy , World First Gene Therapy Thalassemia , Thalassemia , Thalassemia Gene Therapy , Sickle Cell Gene Therapy , Gene Therapy Sickle Cell , World First Gene Therapy Sickle Cell

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2024 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD